Oxford Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Oxford Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,405	Closed	-$885K	–	590
2025 Q2	$885K	Buy	+22,405	New	+$733K	0.29%	73
2019 Q4	–	Sell	-16,113	Closed	-$965K	–	1896
2019 Q3	$965K	Buy	+16,113	New	+$1.05M	0.02%	962
2018 Q3	–	Sell	-9,235	Closed	-$388K	–	1802
2018 Q2	$388K	Buy	+9,235	New	+$409K	0.01%	1428
2017 Q4	–	Sell	-4,471	Closed	-$222K	–	1738
2017 Q3	$222K	Buy	+4,471	New	+$234K	﹤0.01%	1404
2016 Q4	–	Sell	-46,390	Closed	-$1.7M	–	824
2016 Q3	$1.7M	Buy	+46,390	New	+$1.45M	0.05%	433
2016 Q1	–	Sell	-20,049	Closed	-$1.24M	–	845
2015 Q4	$1.24M	Buy	+20,049	New	+$1.08M	0.03%	485
2013 Q4	–	Sell	-298,197	Closed	-$11.2M	–	747
2013 Q3	$11.2M	Sell	298,197 -62,639	-17%	-$1.87M	0.25%	83
2013 Q2	$9.7M	Buy	+360,836	New	+$7.67M	0.26%	89

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxford Asset Management's IONS Position: Q3 2025 in Review

Oxford Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 22,405 shares — an estimated $885K sold.

Oxford Asset Management first reported a position in IONS in Q2 2013 and held it in 8 quarters. The position peaked at $11.2M in Q3 2013. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

Oxford Asset Management reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Oxford Asset Management sold 22,405 Ionis Pharmaceuticals shares in Q3 2025, an estimated $885K.
Oxford Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Oxford Asset Management's Ionis Pharmaceuticals position peaked at $11.2M in Q3 2013.
435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Oxford Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.